Associations - PI3K inhibitor

No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B
No biomarker	Glioblastoma	No biomarker	Glioblastoma	enzastaurin Sensitive: B - Late Trials enzastaurin Sensitive : B	enzastaurin Sensitive: B - Late Trials enzastaurin Sensitive : B
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B	AN2025 Sensitive: B - Late Trials AN2025 Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PI3K inhibitor Sensitive: B - Late Trials PI3K inhibitor Sensitive : B	PI3K inhibitor Sensitive: B - Late Trials PI3K inhibitor Sensitive : B
AKT1 mutation	Triple Negative Breast Cancer	AKT1 mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PTEN mutation	Triple Negative Breast Cancer	PTEN mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	RG7440 Resistant: B - Late Trials RG7440 Resistant : B	RG7440 Resistant: B - Late Trials RG7440 Resistant : B
No biomarker	Glioblastoma	No biomarker	Glioblastoma	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	chidamide Sensitive: B - Late Trials chidamide Sensitive : B	chidamide Sensitive: B - Late Trials chidamide Sensitive : B
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PTEN negative	Prostate Cancer	PTEN negative	Prostate Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PF-05212384 Sensitive: B - Late Trials PF-05212384 Sensitive : B	PF-05212384 Sensitive: B - Late Trials PF-05212384 Sensitive : B
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria trastuzumab + MEN1611 Sensitive : C2	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria trastuzumab + MEN1611 Sensitive : C2
PTEN-L	Triple Negative Breast Cancer	PTEN-L	Triple Negative Breast Cancer	RG7440 Sensitive: C2 – Inclusion Criteria RG7440 Sensitive : C2	RG7440 Sensitive: C2 – Inclusion Criteria RG7440 Sensitive : C2
PIK3CA mutation	HER2 Positive Breast Cancer	PIK3CA mutation	HER2 Positive Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2
PIK3CA mutation	Breast Cancer	PIK3CA mutation	Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C2 – Inclusion Criteria nivolumab + rigosertib Sensitive : C2	nivolumab + rigosertib Sensitive: C2 – Inclusion Criteria nivolumab + rigosertib Sensitive : C2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	chidamide Sensitive: C2 – Inclusion Criteria chidamide Sensitive : C2	chidamide Sensitive: C2 – Inclusion Criteria chidamide Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PI3K inhibitor + fulvestrant Sensitive: C2 – Inclusion Criteria PI3K inhibitor + fulvestrant Sensitive : C2	PI3K inhibitor + fulvestrant Sensitive: C2 – Inclusion Criteria PI3K inhibitor + fulvestrant Sensitive : C2
PTEN mutation	Glioblastoma	PTEN mutation	Glioblastoma	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3	atezolizumab + RG7440 Sensitive: C3 – Early Trials atezolizumab + RG7440 Sensitive : C3
FGF19 amplification + ER positive	HER2 Negative Breast Cancer	FGF19 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
EGFR mutation + ER positive	HER2 Negative Breast Cancer	EGFR mutation + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
AKT1 amplification	Triple Negative Breast Cancer	AKT1 amplification	Triple Negative Breast Cancer	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
AKT1 E17K	Triple Negative Breast Cancer	AKT1 E17K	Triple Negative Breast Cancer	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
KMT2D mutation	Diffuse Large B Cell Lymphoma	KMT2D mutation	Diffuse Large B Cell Lymphoma	chidamide Resistant: C3 – Early Trials chidamide Resistant : C3	chidamide Resistant: C3 – Early Trials chidamide Resistant : C3
FGF3 amplification + ER positive	HER2 Negative Breast Cancer	FGF3 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
FGF4 amplification + ER positive	HER2 Negative Breast Cancer	FGF4 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
PIK3CA E542Q	HER2 Positive Breast Cancer	PIK3CA E542Q	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3

PI3K inhibitor

PI3K inhibitor

Associations(270)

Associations
(270)